Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer

被引:45
作者
Barbieri, F
Lorenzi, P
Ragni, N
Schettini, G
Bruzzo, C
Pedullà, F
Alama, A
机构
[1] Natl Inst Canc Res, Lab Pharmacol & Neurosci, IT-16132 Genoa, Italy
[2] Univ Genoa, Dept Obstet & Gynecol, Genoa, Italy
关键词
cyclin D1; ovarian carcinoma; prognostic factor; survival; Western blot;
D O I
10.1159/000078332
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: In order to assess the prognostic role of the cell-cycle regulator cyclin D1 in epithelial ovarian cancer, 70 patients have been studied during an observation period of 8 years. Methods: The cyclin D1 protein content was analyzed by Western blotting, and classed as negative, positive and highly positive by densitometric scanning. The relationship between cyclin D1 expression and clinicopathological variables was determined. Univariate and multivariate survival analyses were also carried out. Results: Patients with highly positive cyclin D1 tumors had shorter overall survival than patients with positive cyclin D1 ( median survival 31 vs. 49 months; p = 0.058). Furthermore, in patients with stage III/IV tumors and residual disease greater than 2 cm, cyclin D1 expression significantly influenced clinical outcome ( p = 0.047 and 0.040, respectively). In the Cox's regression model, cyclin D1 expression and residual disease were identified as the most important predictors of survival ( p = 0.016 and 0.002, respectively). In patients with high cyclin D1 expression and residual disease after debulking surgery greater than 2 cm, the relative risks of death were to 2.48 and 3.7, respectively, compared to their correspondent counterparts. Conclusion: The overexpression of cyclin D1 is significantly related to a more aggressive tumor phenotype and poor prognosis in ovarian carcinoma. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 25 条
[1]  
Akervall JA, 1997, CANCER, V79, P380
[2]  
Barbieri F, 1999, CLIN CANCER RES, V5, P1837
[3]   Expression of cyclin D1 correlates with malignancy in human ovarian tumours [J].
Barbieri, F ;
Cagnoli, M ;
Ragni, N ;
Pedulla, F ;
Foglia, G ;
Alama, A .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1263-1268
[4]  
Boente MP, 1998, SEMIN ONCOL, V25, P326
[5]   FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS [J].
CAIRNS, P ;
POLASCIK, TJ ;
EBY, Y ;
TOKINO, K ;
CALIFANO, J ;
MERLO, A ;
MAO, L ;
HERATH, J ;
JENKINS, R ;
WESTRA, W ;
RUTTER, JL ;
BUCKLER, A ;
GABRIELSON, E ;
TOCKMAN, M ;
CHO, KR ;
HEDRICK, L ;
BOVA, GS ;
ISAACS, W ;
KOCH, W ;
SCHWAB, D ;
SIDRANSKY, D .
NATURE GENETICS, 1995, 11 (02) :210-212
[6]   On the interpretation of the shortening of the G1-phase by overexpression of cyclins in mammalian cells [J].
Cooper, S .
EXPERIMENTAL CELL RESEARCH, 1998, 238 (01) :110-115
[7]   Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells [J].
Dhar, KK ;
Branigan, K ;
Parkes, J ;
Howells, REJ ;
Hand, P ;
Musgrove, C ;
Strange, RC ;
Fryer, AA ;
Redman, CWE ;
Hoban, PR .
BRITISH JOURNAL OF CANCER, 1999, 81 (07) :1174-1181
[8]  
Diebold J, 2000, J PATHOL, V190, P564, DOI 10.1002/(SICI)1096-9896(200004)190:5<564::AID-PATH569>3.0.CO
[9]  
2-L
[10]   Moderate progress for ovarian cancer in the last 20 years:: prolongation of survival, but no improvement in the cure rate [J].
Engel, J ;
Eckel, R ;
Schubert-Fritschle, G ;
Kerr, J ;
Kuhn, W ;
Diebold, J ;
Kimmig, R ;
Rehbock, J ;
Hölzel, D .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (18) :2435-2445